Intensity Therapeutics Announces New Clinical Data Presentation for its Lead Asset, INT230-6, in Breast Cancer, at the 2021 San Antonio Breast Cancer Symposium® in December'

Press/Media

PeriodNov 30 2021

Media coverage

9

Media coverage